PMX 53 acetate(219639-75-5 free base) NEW
| Price | $113 | $258 | $382 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-15 |
Product Details
| Product Name: PMX 53 acetate(219639-75-5 free base) | CAS No.: 852629-88-0 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2025/07/15 |
Product Introduction
Bioactivity
| Name | PMX 53 acetate(219639-75-5 free base) |
| Description | PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2). |
| In vitro | In HMC-1 cells, PMX-53 (10 nM) inhibits C5a-induced Ca2+ mobilization, but at higher concentrations( ≥30 nM) it causes degranulation in LAD2 mast cells, CD34+ cell-derived mast cells, and RBL-2H3 cells stably expressing MrgX2. Replacement of Trp with Ala and Arg with dArg eliminates the ability of PMX-53 to inhibit C5a-induced Ca2+ mobilization in HMC-1 cells and to cause degranulation in RBL-2H3 cells expressing MrgX2[1]. |
| In vivo | Local pretreatment of rats with PMX-53 (60-180?μg per paw) inhibits zymosan-, carrageenan-, lipopolysaccharide (LPS)- and antigen-induced hypernociception[2]. Pharmacokinetic analyses demonstrate that PMX-53 appears in the plasma within 5 min of oral administration (3 mg/kg) to rats, with peak blood levels of approximately 0.3 μM being reached within 20 min. The plasma elimination half-life was approximately 70 min in this case[3]. |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 95.6 mg/mL (99.98 mM), Sonication and heating are recommended. DMSO : 125 mg/mL (139.49 mM), Sonication is recommended. |
| Keywords | PMX 53 acetate(219639-75-5 free base) | PMX 53 acetate(219639755 free base) | PMX 53 acetate(219639 75 5 free base) | ComplementSystem | Complement System | complement 5a receptor?(C5aR) |
| Inhibitors Related | EG01377 2HCl | Iptacopan hydrochloride | SB290157 trifluoroacetate | BCX 1470 hydrochloride | Complement C5-IN-1 | ADH-503 | CP-289 | Dexamethasone | CP-447697 | Complement factor D-IN-2 | Cyclosporin A | 3-Phenoxybenzaldehyde |
| Related Compound Libraries | Bioactive Compound Library | Peptide Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Preclinical Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $113.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-19 | |
| $0.00/25KG |
VIP1Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-05-16 | |
| $0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY